79 related articles for article (PubMed ID: 9489823)
21. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
22. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
[TBL] [Abstract][Full Text] [Related]
23. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
25. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
27. Safety and pharmacokinetics of recombinant factor XIII in healthy volunteers: a randomized, placebo-controlled, double-blind, multi-dose study.
Visich JE; Zuckerman LA; Butine MD; Gunewardena KA; Wild R; Morton KM; Reynolds TC
Thromb Haemost; 2005 Oct; 94(4):802-7. PubMed ID: 16270634
[TBL] [Abstract][Full Text] [Related]
28. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
Kress HG; OroĊska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
31. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study.
Verbalis JG; Zeltser D; Smith N; Barve A; Andoh M
Clin Endocrinol (Oxf); 2008 Jul; 69(1):159-68. PubMed ID: 18034777
[TBL] [Abstract][Full Text] [Related]
32. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial.
Clements PJ; Furst DE; Wong WK; Mayes M; White B; Wigley F; Weisman MH; Barr W; Moreland LW; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold JR
Arthritis Rheum; 1999 Jun; 42(6):1194-203. PubMed ID: 10366112
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
[TBL] [Abstract][Full Text] [Related]
34. A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis.
Knobler RM; French LE; Kim Y; Bisaccia E; Graninger W; Nahavandi H; Strobl FJ; Keystone E; Mehlmauer M; Rook AH; Braverman I;
J Am Acad Dermatol; 2006 May; 54(5):793-9. PubMed ID: 16635659
[TBL] [Abstract][Full Text] [Related]
35. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
36. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: a phase 1 dose-escalation safety and tolerability study.
Mease PJ; Hobbs K; Chalmers A; El-Gabalawy H; Bookman A; Keystone E; Furst DE; Anklesaria P; Heald AE
Ann Rheum Dis; 2009 Aug; 68(8):1247-54. PubMed ID: 18678578
[TBL] [Abstract][Full Text] [Related]
37. Effect of short-term infusion of recombinant human relaxin on blood pressure in the late-pregnant rhesus macaque (Macaca mulatta).
Golub MS; Working PK; Cragun JR; Cannon RA; Green JD
Obstet Gynecol; 1994 Jan; 83(1):85-8. PubMed ID: 8272314
[TBL] [Abstract][Full Text] [Related]
38. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
[TBL] [Abstract][Full Text] [Related]
39. The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration.
Chen SA; Perlman AJ; Spanski N; Peterson CM; Sanders SW; Jaffe R; Martin M; Yalcinkaya T; Cefalo RC; Chescheir NC
Pharm Res; 1993 Jun; 10(6):834-8. PubMed ID: 8257492
[TBL] [Abstract][Full Text] [Related]
40. Recombinant relaxin: a review of pharmacology and potential therapeutic use.
Gavino ES; Furst DE
BioDrugs; 2001; 15(9):609-14. PubMed ID: 11580304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
